SIRT1 Inhibitor Enhances Hsp90 Inhibitor-mediated Abrogation of Hsp90 Chaperone Function and Potentiates the Cytotoxicity of Hsp90 Inhibitor in Chemo-resistant Human Cancer Cells
![]() |
Moon, Hyun-Jung
(Department of Biochemistry and Pusan National University School of Medicine)
Lee, Su-Hoon (Department of Biochemistry and Pusan National University School of Medicine) Kim, Hak-Bong (Department of Biochemistry and Pusan National University School of Medicine) Lee, Kyoung-A (Department of Biochemistry and Pusan National University School of Medicine) Kang, Chi-Dug (Department of Biochemistry and Pusan National University School of Medicine) Kim, Sun-Hee (Department of Biochemistry and Pusan National University School of Medicine) |
1 | Anckar, J. and Sistonen, L. 2011. Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu. Rev. Biochem. 80, 1089-1115. DOI |
2 | Bagatell, R., Paine-Murrieta, G. D., Taylor, C. W., Pulcini, E. J., Akinaga, S., Benjamin, I. J. and Whitesell, L. 2000. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. 6, 3312-3318. |
3 | Bahr, O., Wick, W. and Weller, M. 2001. Modulation of MDR/MRP by wild-type and mutant p53. J. Clin. Invest. 107, 643-646. DOI |
4 | Banerji, U. 2009. Heat shock protein 90 as a drug target:some like it hot. Clin. Cancer Res. 15, 9-14. DOI |
5 | Brooks, C. L. and Gu, W. 2009. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 9, 123-128. DOI |
6 | Chin, K. V., Ueda, K., Pastan, I. and Gottesman, M. M. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255, 459-462. DOI |
7 | Davenport, E. L., Zeisig, A., Aronson, L. I., Moore, H. E., Hockley, S., Gonzalez, D., Smith, E. M., Powers, M. V., Sharp, S. Y., Workman, P., Morgan, G. J. and Davies, F. E. 2010. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 24, 1804-1807. DOI |
8 | El-Deiry, W. S. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22, 7486-7495. DOI |
9 | Esser, C., Scheffner, M. and Hohfeld, J. 2005. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280, 27443-27448. DOI |
10 | Evans, C. G., Chang, L. and Gestwicki, J. E. 2010. Heat shock protein 70 (hsp70) as an emerging drug target. J. Med. Chem. 53, 4585-4602. DOI |
11 | Fan, M., Park, A. and Nephew, K. P. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptoralpha. Mol. Endocrinol. 19, 2901-2914. DOI |
12 | Freed-Pastor, W. A. and Prives, C. 2012. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286. DOI |
13 | Gan, L. and Mucke, L. 2008. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58, 10-14. DOI |
14 | Guo, F., Rocha, K., Bali, P., Pranpat, M., Fiskus, W., Boyapalle, S., Kumaraswamy, S., Balasis, M., Greedy, B., Armitage, E. S., Lawrence, N. and Bhalla, K. 2005. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65, 10536-10544. DOI |
15 | Hong, D. S., Banerji, U., Tavana, B., George, G. C., Aaron, J. and Kurzrock, R. 2013. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat. Rev. 39, 375-387. DOI |
16 | Kim, D. Y., Kim, M. J., Kim, H. B., Lee, J. W., Bae, J. H., Kim, D. W., Kang, C. D. and Kim, S. H. 2011. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim. Biophys. Acta 1812, 796-805. DOI |
17 | Jhaveri, K., Taldone, T., Modi, S. and Chiosis, G. 2012. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823, 742-755. DOI |
18 | Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C. and Burrows, F. J. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410. DOI |
19 | Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J. and Reynolds, C. P. 2001. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185-6193. |
20 | Kim, H. B., Lee, S. H., Um, J. H., Kim, M. J., Hyun, S. K., Gong, E. J., Oh, W. K., Kang, C. D. and Kim, S. H. 2015. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int. J. Biol. Sci. 11, 923-934. DOI |
21 | Li, D., Marchenko, N. D. and Moll, U. M. 2011. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 18, 1904-1913. DOI |
22 | Li, D., Marchenko,N. D., Schulz,R., Fischer,V., Velasco-Hernandez, T., Talos, F. and Moll, U. M. 2011. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 9, 577-588. DOI |
23 | Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D′Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A. L. and Hudis, C. 2011. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139. DOI |
24 | Li, D., Yallowitz, A., Ozog, L. and Marchenko, N. 2014. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis. 5, e1194. DOI |
25 | McCollum, A. K., Teneyck, C. J., Sauer, B. M., Toft, D. O. and Erlichman, C. 2006. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66, 10967-10975. DOI |
26 | McCollum, A. K., TenEyck, C. J., Stensgard, B., Morlan, B. W., Ballman, K. V., Jenkins, R. B., Toft, D. O. and Erlichman, C. 2008. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 68, 7419-7427. DOI |
27 | Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., Vu, L. P., Zhao, X., Zatorska, D., Taldone, T., Smith-Jones, P., Alpaugh, M., Gross, S. S., Pillarsetty, N., Ku, T., Lewis, J. S., Larson, S. M., Levine, R., Erdjument-Bromage, H., Guzman, M. L., Nimer, S. D., Melnick, A., Neckers, L. and Chiosis, G. 2011. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 7, 818-826. DOI |
28 | Muller, P., Hrstka, R., Coomber, D., Lane, D. P. and Vojtesek, B. 2008. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27, 3371-3383. DOI |
29 | Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, F., Walton, M., Judson, I., Workman, P. and Eisen, T. 2012. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest. New Drugs 30, 341-349. DOI |
30 | Oh, W. K., Cho, K. B., Hien, T. T., Kim, T. H., Kim, H. S., Dao, T. T., Han, H. K., Kwon, S. M., Ahn, S. G., Yoon, J. H., Kim, T. H., Kim, Y. G. and Kang, K. W. 2010. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 78, 855-864. DOI |
31 | Piper, P. W. and Millson, S. H. 2011. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals 4, 1400-1422. DOI |
32 | Powers, M. V. and Workman, P. 2007. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 581, 3758-3769. DOI |
33 | Richardson, P. G., Chanan-Khan, A. A., Lonial, S., Krishnan, A. Y., Carroll, M. P., Alsina, M., Albitar, M., Berman, D., Messina, M. and Anderson, K. C. 2011. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br. J. Haematol. 153, 729-740. DOI |
34 | Richardson, P. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A. and Anderson, K. C. 2011. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152, 367-379. DOI |
35 | Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P. and Schuetz, J. D. 2001. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J. Biol. Chem. 276, 39359-39367. DOI |
36 | Taldone, T., Gozman, A., Maharaj, R. and Chiosis, G. 2008. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370-374. DOI |
37 | Solit, D. B., Osman, I., Polsky, D., Panageas, K. S., Daud, A., Goydos, J. S., Teitcher, J., Wolchok, J. D., Germino, F. J., Krown, S. E., Coit, D., Rosen, N. and Chapman, P. B. 2008. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14, 8302-8307. DOI |
38 | Strauss, B. E. and Haas, M. 1995. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem. Biophys. Res. Commun. 217, 333-340. DOI |
39 | Takara, K., Sakaeda, T. and Okumura, K. 2006. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12, 273-286. DOI |
40 | Vilaboa, N. E., Galan, A., Troyano, A., de Blas, E. and Aller, P. 2000. Regulation of multidrug resistance 1 (MDR1)/Pglycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J. Biol. Chem. 275, 24970-24976. DOI |
41 | Westerheide, S. D., Anckar, J., Stevens, S. M., Jr., Sistonen, L. and Morimoto, R. I. 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323, 1063-1066. DOI |
42 | Yamakuchi, M. and Lowenstein, C. J. 2009. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8, 712-715. DOI |
![]() |